U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H19N3O
Molecular Weight 293.3636
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ONDANSETRON

SMILES

Cc1nccn1CC2CCc3c(c4ccccc4n3C)C2=O

InChI

InChIKey=FELGMEQIXOGIFQ-UHFFFAOYSA-N
InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C18H19N3O
Molecular Weight 293.3636
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68017294 | https://www.ncbi.nlm.nih.gov/pubmed/11474424

Ondansetron (ZOFRAN®) is a selective 5-HT3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by radiotherapy, anesthesia, surgery or cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. While its mechanism of action has not been fully characterized, ondansetron is not a dopamine-receptor antagonist. It is not certain whether ondansetron's antiemetic action is mediated centrally, peripherally, or in both sites. However, cytotoxic chemotherapy appears to be associated with release of serotonin from the enterochromaffin cells of the small intestine. The released serotonin may stimulate the vagal afferents through the 5-HT3 receptors and initiate the vomiting reflex.

Originator

Curator's Comment:: Glaxo Wellcome is a predecessor of GlaxoSmithKline plc.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
8.31 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
ZOFRAN

Approved Use

Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥50 mg/m2. Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. Prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, ZOFRAN® is recommended even where the incidence of postoperative nausea and/or vomiting is low.

Launch Date

7.2567357E11
Preventing
ZOFRAN

Approved Use

Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥50 mg/m2. Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. Prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, ZOFRAN® is recommended even where the incidence of postoperative nausea and/or vomiting is low.

Launch Date

7.2567357E11
Preventing
ZOFRAN

Approved Use

Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥50 mg/m2. Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. Prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, ZOFRAN® is recommended even where the incidence of postoperative nausea and/or vomiting is low.

Launch Date

7.2567357E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
125.8 ng/mL
24 mg single, oral
dose: 24 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ONDANSETRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
194.4 ng/mL
24 mg single, oral
dose: 24 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ONDANSETRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
26.2 ng/mL
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ONDANSETRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
42.7 ng/mL
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ONDANSETRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
30.196 ng/mL
8 mg single, oral
dose: 8 mg
route of administration: oral
experiment type: single
co-administered:
ONDANSETRON plasma
Homo sapiens
32.096 ng/mL
8 mg single, oral
dose: 8 mg
route of administration: oral
experiment type: single
co-administered:
ONDANSETRON plasma
Homo sapiens
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
224.155 ng*h/mL
8 mg single, oral
dose: 8 mg
route of administration: oral
experiment type: single
co-administered:
ONDANSETRON plasma
Homo sapiens
270.927999999999 ng*h/mL
8 mg single, oral
dose: 8 mg
route of administration: oral
experiment type: single
co-administered:
ONDANSETRON plasma
Homo sapiens
237.935 ng*h/mL
8 mg single, oral
dose: 8 mg
route of administration: oral
experiment type: single
co-administered:
ONDANSETRON plasma
Homo sapiens
293.491999999999 ng*h/mL
8 mg single, oral
dose: 8 mg
route of administration: oral
experiment type: single
co-administered:
ONDANSETRON plasma
Homo sapiens
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.7 h
24 mg single, oral
dose: 24 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ONDANSETRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5.8 h
24 mg single, oral
dose: 24 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ONDANSETRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
3.1 h
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ONDANSETRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
3.5 h
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ONDANSETRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
27%
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ONDANSETRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer








Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >100 uM]
yes [IC50 0.15 uM]
yes (co-administration study)
Comment: [PMID:23241029]: IC50 = 0.3 uM; Ondansetron treatment caused a statistically significantly higher Cmax of metformin compared with placebo and apparently decreased the renal clearance of metformin by 37%
yes [IC50 0.89 uM]
yes [IC50 17.4 uM]
yes [IC50 6.9 uM]
yes (co-administration study)
Comment: [PMID:23241029]: IC50 = 0.16 uM; Ondansetron treatment caused a statistically significantly higher Cmax of metformin compared with placebo and apparently decreased the renal clearance of metformin by 37%
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes
likely (co-administration study)
Comment: inducers or inhibitors of CYP1A2 may change the clearance and, hence, the half-life of ondansetron
yes
likely (co-administration study)
yes
yes (co-administration study)
Comment: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. However, on the basis of available data, no dosage adjustment for ZOFRAN is recommended for patients on these drugs.
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain.
1987 Dec
Ondansetron: a new entity in emesis control.
1990 Nov
Progress in the control of acute and delayed emesis induced by cisplatin.
1991
Cardiorespiratory decompensation following methylprednisolone administration.
1993 Jul-Sep
Extrapyramidal reaction caused by ondansetron.
1994 Feb
Nephrogenic diabetes insipidus following high dose epirubicin chemotherapy for metastatic soft tissue sarcoma.
1995
Ondansetron-induced headache. Our experience in gynecological cancer.
1995
Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen.
1995 Aug
Dysphoria after treatment with ondansetron.
1995 Jul
The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery.
1995 Jul
Managing an extrapyramidal reaction caused by ondansetron.
1995 May
Inhibitory effect of ethanol on the 5-hydroxytryptamine-induced Bezold-Jarisch reflex--involvement of peripheral 5-HT3 receptors.
1995 May 26
Acute myocardial infarction in man treated with epirubicin for non-Hodgkin lymphoma.
1995 Oct
A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation.
1995 Sep
Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
2005 Dec
Ondansetron-induced extrapyramidal symptoms during cesarean section.
2005 Oct
Antiemetic-related dystonic reaction unmasked by removal of a scopolamine transdermal patch.
2006 Apr
Interaction between tramadol and two anti-emetics on nociception and gastrointestinal transit in mice.
2006 Oct
Can dantrolene contribute to methotrexate toxicity?
2006 Sep
Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy.
2007 Apr
Chronic fluoxetine treatment increases the expression of PSA-NCAM in the medial prefrontal cortex.
2007 Apr
Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost.
2007 Apr-May
Comparison of the effectiveness of metoclopramide, ondansetron, and granisetron on the prevention of nausea and vomiting after laparoscopic cholecystectomy.
2007 Dec
Reversal of cocaine-induced behavioral sensitization and associated phosphorylation of the NR2B and GluR1 subunits of the NMDA and AMPA receptors.
2007 Feb
Interactions between metoclopramide and morphine: enhanced antinociception and motor dysfunction in rats.
2007 Jan-Feb
Spinal NK-1 receptor expressing neurons mediate opioid-induced hyperalgesia and antinociceptive tolerance via activation of descending pathways.
2007 May
Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study.
2008 Aug
Ondansetron-associated hypokalemia in a 2-year-old with pre-B-cell ALL.
2008 Jan
Ondansetron and carpopedal spasm.
2008 Jan
Ondansetron given intravenously attenuates arterial blood pressure drop due to spinal anesthesia: a double-blind, placebo-controlled study.
2008 Jul-Aug
Neonatal extrapyramidal movements. Neonatal withdrawal due to maternal citalopram and ondansetron use.
2008 Mar
Ondansetron and seizures.
2009 Dec
A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline.
2009 Feb
Coronary vasospasm and atrial fibrillation associated with ondansetron therapy.
2009 Mar
Acute anti-emetic withdrawal associated with a hemorrhagic cerebellar arteriovenous malformation.
2010 Aug
Ondansetron-induced headache in a parturient mimicking postdural puncture headache.
2010 Feb
The lesser of two adverse reactions.
2010 Jan
Clinical trial: oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children--a double-blind randomized study.
2010 Jan
Multimodal prevention of pain, nausea and vomiting after breast cancer surgery.
2010 Oct
Ondansetron-induced migraine-type headache.
2010 Sep
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
2011 Apr 10
In vivo assessment of antiemetic drugs and mechanism of lycorine-induced nausea and emesis.
2011 Dec
Pemirolast reduces cisplatin-induced kaolin intake in rats.
2011 Jul 1
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
2011 May 12
Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.
2011 Oct
Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
2011 Sep
Prophylaxis of radiation-induced nausea and vomiting using 5-hydroxytryptamine-3 serotonin receptor antagonists: a systematic review of randomized trials.
2012 Jan 1
Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs).
2013 Nov 15
Intestinal obstruction in pregnancy by ondansetron.
2014 Dec
Patents

Sample Use Guides

To prevent nausea and vomiting associated with cancer chemotherapy the recommended adult oral dosage of ondansetron (ZOFRAN®) is a single 24-mg tablet administered 30 minutes before the start of single-day highly emetogenic chemotherapy; for moderately emetogenic cancer chemotherapy the recommended adult oral dosage is one 8-mg ondansetron (ZOFRAN®) tablet given twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy: the first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. To prevent nausea and vomiting associated with radiotherapy the recommended adult oral dosage is one 8-mg ondansetron (ZOFRAN®) tablet given 3 times a day; for total body irradiation, one 8-mg ondansetron (ZOFRAN®) tablet should be administered 1 to 2 hours before each fraction of radiotherapy administered each day; for single high-dose fraction radiotherapy to the abdomen, one 8-mg ondansetron (ZOFRAN®) tablet should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy; for daily fractionated radiotherapy to the abdomen, one 8-mg ondansetron (ZOFRAN®) tablet should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day radiotherapy is given. To prevent postoperative nausea and vomiting the recommended adult oral dosage is 16 mg given as two 8-mg ondansetron (ZOFRAN®) tablets 1 hour before induction of anesthesia.
Route of Administration: Oral
In Vitro Use Guide
On the isolated vagus nerve and superior cervical ganglion of the rat, R,S-GR38032F (ondansetron) behaved as a reversible competitive antagonist of 5-HT-induced depolarization with pKB values of 8.61+/-0.08 (n=19) and 8.13+/-0.07 (n=16), respectively. The resolved R- and S-isomers of GR38032F were approximately equipotent as 5-HT antagonists on the rat vagus nerve: the pKB values were 8.95+/-0.05 (n=16) and 8.63+/-0.08 (n=17), respectively. R,S-GR38032F was also an effective antagonist of 5-HT on the rabbit isolated vagus nerve: in this case the pKB value was 9.40+/-0.14 (n=4).
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:04:27 UTC 2021
Edited
by admin
on Fri Jun 25 21:04:27 UTC 2021
Record UNII
4AF302ESOS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ONDANSETRON
INN   JAN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
ONDANSETRON [MI]
Common Name English
(+/-)-2,3-DIHYDRO-9-METHYL-3-((2-METHYLIMIDAZOL-1-YL)METHYL)CARBAZOL-4(1H)-ONE
Systematic Name English
A04AA01
Code English
ONDANSETRON [MART.]
Common Name English
EUR-1025
Code English
ONDANSETRON [INN]
Common Name English
4H-CARBAZOL-4-ONE, 1,2,3,9-TETRAHYDRO-9-METHYL-3-((2-METHYL-1H-IMIDAZOL-1-YL)METHYL)- (+/-)-
Systematic Name English
NSC-757870
Code English
ONDANSETRON [WHO-DD]
Common Name English
ONDANSETRON [VANDF]
Common Name English
ONDANSETRON [USP MONOGRAPH]
Common Name English
ZOFRAN ODT
Brand Name English
ONDANSETRON [ORANGE BOOK]
Common Name English
ONDANSETRON [JAN]
Common Name English
ONDANSETRON [USP-RS]
Common Name English
Classification Tree Code System Code
WHO-ESSENTIAL MEDICINES LIST 17.2
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 8.4
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
LIVERTOX 711
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
NCI_THESAURUS C267
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
NDF-RT N0000175818
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
NDF-RT N0000175817
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
WHO-VATC QA04AA01
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
WHO-ATC A04AA01
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
NCI_THESAURUS C94726
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
FDA ORPHAN DRUG 491115
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
Code System Code Type Description
FDA UNII
4AF302ESOS
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
PRIMARY
MESH
D017294
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
PRIMARY
DRUG CENTRAL
1992
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
PRIMARY
HSDB
8304
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
PRIMARY
MERCK INDEX
M8213
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
PRIMARY Merck Index
LACTMED
Ondansetron
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
PRIMARY
INN
5965
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
PRIMARY
WIKIPEDIA
ONDANSETRON
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
PRIMARY
EVMPD
SUB09445MIG
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
PRIMARY
RXCUI
26225
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
PRIMARY RxNorm
PUBCHEM
4595
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
PRIMARY
IUPHAR
2290
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
PRIMARY
EPA CompTox
99614-02-5
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
PRIMARY
ChEMBL
CHEMBL46
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
PRIMARY
NCI_THESAURUS
C1119
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
PRIMARY
DRUG BANK
DB00904
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
PRIMARY
CAS
99614-02-5
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
PRIMARY
USP_CATALOG
1478571
Created by admin on Fri Jun 25 21:04:27 UTC 2021 , Edited by admin on Fri Jun 25 21:04:27 UTC 2021
PRIMARY USP-RS
Related Record Type Details
TARGET -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
METABOLIC ENZYME -> INHIBITOR
IC50
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
IC50
BINDER->LIGAND
BINDING
TRANSPORTER -> SUBSTRATE
Related Record Type Details
METABOLITE INACTIVE -> PARENT
METABOLITE -> PARENT
METABOLITE ACTIVE -> PARENT
Multiple P450 isoforms; Not found in plasma at concentrations likely to significantly contribute to the biological activity of ondansetron
METABOLITE -> PARENT
multiple CYP isoforms
METABOLITE -> PARENT
Multiple CYP isoforms
METABOLITE -> PARENT
Multiple CYP isoenzymes
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Children <15 Years
PHARMACOKINETIC